Successful effect of triple blockade of renin-angiotensin-aldosterone system on massive proteinuria in a patient with chronic kidney disease

Clinical and Experimental Nephrology

Volumn 13, Issue 6, 2009, Pages 663-666

  Kuriyama, Satoru ^a   Sugano, Naoki ^a   Ueda, Hiroyuki ^a   Otsuka, Yasushi ^a   Kanzaki, Go ^a   Hosoya, Tatsuo ^b  

^a SAISEIKAI CENTRAL HOSPITAL   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

ACE I; ARB; CKD; Eplerenone

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG DERIVATIVE; EPLERENONE; MINERALOCORTICOID RECEPTOR; SPIRONOLACTONE;

ARTICLE; CASE REPORT; CHRONIC KIDNEY FAILURE; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; MALE; MEMBRANOUS GLOMERULONEPHRITIS; MIDDLE AGED; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROTEINURIA; RECEPTORS, MINERALOCORTICOID; RENIN-ANGIOTENSIN SYSTEM; SPIRONOLACTONE;

EID: 76249089792     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-009-0213-3     Document Type: Article

References (14)

1. Russo D, Minutolo R, Pisani A, Esposito R, Signoriello G, Andreucci M, et al. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis. 2001;38:18-25. (Pubitemid 32611753)
2. Russo D, Pisani A, Belletta MM, De Nicola L, Savino FA, Andreucci M, et al. Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis. 1999;33:851-6. (Pubitemid 29214680)
3. Kuriyama S, Tomonari H, Abe A, Imasawa T, Hosoya T. Beneficial effect of combination therapy with angiotensin II receptor antagonist and angiotensin converting enzyme inhibitor on overt proteinuria in a patient with type I diabetic nephropathy. Nephron. 2000;86:529-30. (Pubitemid 32008859)
4. Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, et al. Randomized controlled trial of dual blockade of renin angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. Brit Med J. 2000;321:1440-4.
5. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin II receptor blocker and angiotensin converting enzyme inhibitor in non-diabetic renal disease COOPERATE: a randomized controlled trial. Lancet. 2003;361:117-24. (Pubitemid 36092015)
6. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomized, double-blind, controlled trial. Lancet. 2008;372:547-53.
7. Takeda Y, Yoneda T, Demura M, Furukawa K, Miyamori I, Mabuchi H. Effects of sodium intake on cardiovascular aldosterone synthesis in stroke-prone spontaneously hypertensive rats. J Hypertens. 2001;19:635-9. (Pubitemid 32280957)
8. Nagase M, Matsui H, Shibata S, Gotoda T, Fujita T. Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor: Role of oxidative stress. Hypertension. 2007;50:877-83. (Pubitemid 350287529)
9. Bianchi S, Bigazzi R, Campese VM. Long-term effect of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int. 2006;70:2116-23. (Pubitemid 44871374)
10. Schjoedt KJ, Rossing K, Juhl TR, Boomsma F, Tarnow L, Rossing P, et al. Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int. 2005;68:2829-36. (Pubitemid 43251030)
11. Furumatsu Y, Nagasawa Y, Tomida K, Mikami S, Kaneko T, Okada N, et al. Effect of renin angiotensin aldosterone system triple blockade on non-diabetic renal disease: Addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin converting enzyme inhibitor with an angiotensin II receptor blocker. Hypertens Res. 2008;31:59-67. (Pubitemid 351325616)
12. Tylicki L, Rutkowski P, Renke M, Larcznski W, Aleksandrowicz E, Lysiak-Szydlowska W, et al. Triple pharmacological blockade of the renin angiotensin aldosterone system in non-diabetic CKD: An open-label crossover randomized controlled trial. Am J Kidney Dis. 2008;52:486-93.
13. Rogerson F, Yao Y, Smith BJ, Fuller PJ. Differences in the determinants of eplerenone, spironolactone and aldosterone binding to the mineralocorticoid receptor. Clin Exp Pharmacol Physiol. 2004;31:704-9. (Pubitemid 39540321)
14. Garthwaite SM, McMahon EG. The evolution of aldosterone antagonists. Mol Cell Endocrinol. 2004;217:27-31. (Pubitemid 38596625)